tanshinone has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, F; Feng, Y; Jiang, M; Liu, Z; Sun, X; Wu, Z; Xie, F; Zheng, C; Zhou, Z | 1 |
| Feng, J; Yan, J; Yang, X | 1 |
2 other study(ies) available for tanshinone and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Tanshinone IIA attenuates demyelination and promotes remyelination in
Topics: Abietanes; Albendazole; Angiostrongylus cantonensis; Animals; Blotting, Western; Demyelinating Diseases; Fluorescent Antibody Technique; Interleukin-1beta; Interleukin-6; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Myelin Sheath; Nitric Oxide Synthase Type II; Remyelination; Strongylida Infections; Tumor Necrosis Factor-alpha | 2019 |
Treatment with tanshinone IIA suppresses disruption of the blood-brain barrier and reduces expression of adhesion molecules and chemokines in experimental autoimmune encephalomyelitis.
Topics: Abietanes; Animals; Blood-Brain Barrier; Calcium-Binding Proteins; Cell Adhesion Molecules; Chemokines; Demyelinating Diseases; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Glial Fibrillary Acidic Protein; Microfilament Proteins; Movement Disorders; Rats; Rats, Inbred Lew; Tight Junction Proteins | 2016 |